Eli Lilly Builds Dual Growth Engine as Weight-Loss and Cancer Data Bolster Case for Further Gains

Eli Lilly posts strong Q1 earnings, unveils groundbreaking weight-loss data for Retatrutide and positive cancer results for Retevmo, driving shares near 52-week high.

Eli Lilly is forging a rare two-front narrative that gives investors something beyond the blockbuster obesity franchise. With striking clinical results from both its oncology pipeline and its next-generation weight-loss therapy landing in quick succession, the drugmaker is making the case that its growth story runs much deeper than any single drug class.

The stock closed at €975.80 on Friday, gaining 0.75% and leaving it less than 1% shy of its 52-week high of €985.00. Over the past month, the shares have climbed 16.07%, and the 12-month gain stands at 45.75%. The relative strength index sits at 68.2, signalling strong momentum even if the entry point has become less forgiving.

Blockbuster Quarter Sets the Stage

Those share price gains rest on a foundation of operational outperformance. Eli Lilly reported first-quarter revenue of $19.8 billion, a 55.5% jump from a year earlier. Adjusted earnings per share came in at $8.55, well above the $6.97 analysts had anticipated.

Management’s full-year 2026 outlook calls for revenue between $82 billion and $85 billion, representing expected growth of roughly 28%. The earnings per share target range of $35.50 to $37.00 would mark a 49.7% increase from the prior year. The market, in other words, is already pricing in continued acceleration rather than mere stability.

Obesity’s New Frontier: Retatrutide Delivers Unprecedented Weight Loss

The obesity story took a powerful new turn with data from the phase 3 TRIUMPH-1 study of Retatrutide. The triple agonist, which targets three distinct receptors, produced an average weight loss of 28.3% over 80 weeks in the highest dose group. Nearly half of the participants in that cohort shed at least 30% of their body weight, a level of efficacy previously attainable only through bariatric surgery.

Analysts described the results as unprecedented. Yet the therapy’s strong effect comes with a notable side-effect burden: about 11% of patients in the highest dose group discontinued the trial because of adverse events. Eli Lilly is also pushing ahead with Foundayo, its own oral GLP-1 drug for weight reduction, which recently secured FDA approval.

Cancer Data Add a Second Pillar

On the oncology front, Eli Lilly showcased the strength of Retevmo (selpercatinib) at the ASCO 2026 congress. The phase 3 LIBRETTO-432 study showed that the therapy cut the risk of relapse or death by 83% compared with placebo. After two years, the event-free survival rate stood at 92% in the Retevmo group versus 61% in the control arm. The results, published simultaneously in the New England Journal of Medicine, are expected to underpin planned regulatory submissions.

These data are meaningful beyond the immediate clinical implications. They demonstrate that Eli Lilly’s growth does not depend solely on the weight-loss market. For a company trading at a valuation that already reflects high expectations, a broader base of catalysts is exactly what investors want to see.

An unexpected tailwind is emerging from the GLP-1 class itself. On the same ASCO platform, researchers from the University of Pennsylvania presented data from a study of more than 111,000 women, showing that GLP-1 use was associated with an approximately 30% reduction in breast cancer risk. Additional findings pointed to slower disease progression in lung and liver cancer. These observations could widen the addressable market for Eli Lilly’s metabolic drugs significantly over the long term.

Diversification Through Deal-Making

Management is not relying solely on internal pipeline progress. Eli Lilly has been on a spending spree to reduce its dependence on the obesity franchise. The company is acquiring Centessa Pharmaceuticals for roughly $7.8 billion, and other purchases amounting to nearly $4 billion are also in the works. The strategic focus of this M&A push is vaccines and rare diseases, areas that could add further revenue streams beyond the core metabolic business.

Institutional investors have taken note. Daiwa Securities increased its stake in the fourth quarter by 6.7%, lifting its holding to more than 137,000 shares. The company’s market capitalisation now stands at approximately $1.06 trillion, a reflection of the market’s conviction that Eli Lilly’s run has further to go.

The Near-Term Catalysts

What matters in the coming weeks are two regulatory milestones: the filing of Retevmo based on the LIBRETTO-432 data and the commercial rollout of Foundayo. Both will be critical in determining whether the stock can finally break above the €985.00 barrier and set a new all-time high. Until then, the record level remains the clearest benchmark for traders watching a stock that has already delivered a 45.75% annual gain.